Literature DB >> 25882517

Propranolol Dosing Practices in Adult Burn Patients: Implications for Safety and Efficacy.

David A Brown1, Janet Gibbons, Shari Honari, Matthew B Klein, Tam N Pham, Nicole S Gibran.   

Abstract

Studies in children with burn injuries have demonstrated that propranolol improves metabolism and reduces muscle protein wasting. However, safety and efficacy in adults are less well established than in children. The purpose of this study was to determine safety of propranolol use in adult patients with burn injuries. Medical records were reviewed for burn-injured adults receiving propranolol. Patients between 18 and 65 years old and with ≥20% TBSA burn were included. Fifty-four patients met the criteria with mean age of 37 years and mean burn size of 38% TBSA. Propranolol dosages ranged from 0.1 to 3.8 mg/kg/day, with an average maximum dosage of 0.61 mg/kg/day. Mean heart rate decreased by 25% during 4 weeks. Seventy-two percent of patients experienced at least one episode of hypotension and 15% experienced bradycardia. Propranolol doses were most frequently held for low blood pressure; 32% of patients had at least one dose held for hypotension. This retrospective analysis suggests that modest dosing of propranolol results in frequent episodes of hypotension or bradycardia. Our data suggest that adults do not tolerate the higher doses reported in a pediatric population. Despite potential beneficial anti-catabolic effects of propranolol, burn care providers must recognize potential iatrogenic hemodynamic effects of this intervention. Our data support the need for prospective multicenter studies to delineate the safety and efficacy of propranolol in adult burn-injured patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 25882517     DOI: 10.1097/BCR.0000000000000240

Source DB:  PubMed          Journal:  J Burn Care Res        ISSN: 1559-047X            Impact factor:   1.845


  6 in total

Review 1.  Anabolic and anticatabolic agents used in burn care: What is known and what is yet to be learned.

Authors:  Eduardo I Gus; Shahriar Shahrokhi; Marc G Jeschke
Journal:  Burns       Date:  2019-12-15       Impact factor: 2.744

Review 2.  Taming the Flames: Targeting White Adipose Tissue Browning in Hypermetabolic Conditions.

Authors:  Abdikarim Abdullahi; Marc G Jeschke
Journal:  Endocr Rev       Date:  2017-12-01       Impact factor: 19.871

3.  Propranolol kinetics in plasma from severely burned adults.

Authors:  Ashley N Guillory; David N Herndon; Michael B Silva; Clark R Andersen; Erge Edgu-Fry; Oscar E Suman; Celeste C Finnerty
Journal:  Burns       Date:  2017-06-20       Impact factor: 2.744

4.  The Safety and Efficacy of Propranolol in Reducing the Hypermetabolic Response in the Pediatric Burn Population.

Authors:  Sylvia Ojeda; Emily Blumenthal; Pamela Stevens; Clark R Andersen; Lucy Robles; David N Herndon; Walter J Meyer
Journal:  J Burn Care Res       Date:  2018-10-23       Impact factor: 1.845

Review 5.  Burn-induced hypermetabolism and skeletal muscle dysfunction.

Authors:  Carly M Knuth; Christopher Auger; Marc G Jeschke
Journal:  Am J Physiol Cell Physiol       Date:  2021-04-28       Impact factor: 5.282

Review 6.  Safety and effectiveness of propranolol in severely burned patients: systematic review and meta-analysis.

Authors:  Ramiro Manzano-Nunez; Herney Andrés García-Perdomo; Paula Ferrada; Carlos Alberto Ordoñez Delgado; Diego Andrés Gomez; Jorge Esteban Foianini
Journal:  World J Emerg Surg       Date:  2017-03-02       Impact factor: 5.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.